Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679799 | 0.89 | SCN9A (0.48) | SCN9AHPGDTSHRHTTSMN1; SMN2 | |
| SCHEMBL680674 | 0.88 | SCN9A (0.57) | SOS1SCN9ABCL2L1MCL1ACLY | |
| SCHEMBL679943 | 0.88 | SCN9A (0.57) | SCN9AACLY | |
| SCHEMBL680594 | 0.85 | SCN9A (0.52) | SCN9APTPN1 | |
| SCHEMBL703171 | 0.85 | BCL2L1 (0.59) | SOS1SCN9AHPGDTSHRHTT | |
| SCHEMBL679760 | 0.84 | BCL2L1 (0.49) | SCN9AHPGDTSHRHTTSMN1; SMN2 | |
| SCHEMBL678831 | 0.83 | BCL2L1 (0.52) | SCN9AHPGDTSHRHTTSMN1; SMN2 | |
| SCHEMBL679902 | 0.82 | SCN9A (0.56) | SCN9ASMN1; SMN2PTPN1BCL2L1MCL1 | |
| SCHEMBL16319859 | 0.82 | MMP1 (0.56) | SCN9AHPGDTSHRHTTSMN1; SMN2 | |
| SCHEMBL680642 | 0.81 | SCN9A (0.50) | SCN9APTPN1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | SOS1 397/4885SCN9A 13/4885HPGD 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.